Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
35.75 (USD) • At close July 3, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 10.094 | 7.768 | 9.027 | 0 | 2.914 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 7.765 | 4.741 | 1.001 | 62.86 | 33.488 | 28.828 | 26.322 | 21.291 | 38.969 | 48.162 | 27.656 | 10.888 | 6.661 | 3.379 | 0 | 0.017 | 0.007 |
| Gross Profit
| 2.329 | 3.027 | 8.026 | -62.86 | -30.574 | -28.828 | -26.322 | -21.291 | -38.969 | -48.162 | -27.656 | -10.888 | -6.661 | -3.379 | 0 | -0.017 | -0.007 |
| Gross Profit Ratio
| 0.231 | 0.39 | 0.889 | 0 | -10.492 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 39.972 | 86.655 | 81.876 | 68.838 | 36.157 | 18.192 | 17.558 | 13.342 | 28.533 | 35.504 | 18.617 | 4.65 | 2.583 | 1.158 | 0 | 0 | 0 |
| General & Administrative Expenses
| 16.812 | 34.752 | 30.215 | 23.555 | 14.354 | 10.636 | 8.764 | 7.949 | 10.436 | 12.658 | 9.039 | 6.238 | 4.078 | 2.22 | 0.014 | 0.014 | 0.014 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 40.101 | 34.752 | 30.215 | 23.555 | 14.354 | 10.636 | 8.764 | 7.949 | 10.436 | 12.658 | 9.039 | 6.238 | 4.078 | 2.22 | 0.014 | 0.014 | 0.014 |
| Other Expenses
| -0.593 | 0 | 0 | 29.479 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.002 | 0 | 0.004 | 0 | 0 |
| Operating Expenses
| 80.073 | 121.407 | 112.091 | 92.393 | 50.511 | 28.828 | 26.322 | 21.291 | 38.969 | 48.162 | 27.656 | 10.888 | 6.661 | 3.379 | 0.018 | 0.014 | 0.014 |
| Operating Income
| -77.744 | -118.38 | -112.053 | -92.393 | -50.511 | -28.828 | -26.322 | -21.291 | -38.969 | -48.162 | -27.656 | -10.888 | -6.661 | -3.379 | -0.018 | -0.031 | -0.021 |
| Operating Income Ratio
| -7.702 | -15.239 | -12.413 | 0 | -17.334 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -52.249 | 1.722 | 1.873 | 0.025 | 0.048 | 0.21 | 0.233 | 0.168 | 0.127 | 0.108 | 0.04 | 0.004 | -2.788 | -0.092 | -1.943 | 0 | 0 |
| Income Before Tax
| -130.036 | -116.658 | -110.218 | -92.287 | -50.463 | -28.618 | -26.089 | -21.123 | -38.842 | -48.054 | -27.616 | -10.884 | -9.45 | -3.47 | 0 | 0 | 0 |
| Income Before Tax Ratio
| -12.883 | -15.018 | -12.21 | 0 | -17.317 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -1.167 | 0 | 5.396 | -92.42 | -0.007 | -0.236 | 0.233 | -0.07 | -0.206 | -0.161 | -0.036 | -0.017 | 1.615 | 3.379 | 0.018 | 0.031 | 0.021 |
| Net Income
| -130.036 | -116.658 | -116.877 | -92.287 | -52.174 | -31.092 | -29.355 | -21.123 | -38.842 | -48.054 | -27.616 | -10.884 | -0.009 | -3.47 | -0.018 | -0.031 | -0.021 |
| Net Income Ratio
| -12.883 | -15.018 | -12.947 | 0 | -17.905 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -3,504 | -6,368.84 | -811.68 | -1,666 | -5,056 | -3,866 | -18,064.62 | -54,023.02 | -199,189.74 | -511,212.77 | -511,407.41 | -375,310.34 | -945,000 | -578,352.17 | -1,964,470 | -30,867 | -21,134 |
| EPS Diluted
| -3,504 | -6,368.84 | -811.68 | -1,666 | -5,056 | -3,866 | -18,064.62 | -54,023.02 | -199,189.74 | -511,212.77 | -511,407.41 | -375,310.34 | -945,000 | -578,352.17 | -1,964,470 | -30,867 | -21,134 |
| EBITDA
| -74.937 | -114.089 | -110.838 | -92.262 | -50.484 | -28.802 | -26.268 | -21.059 | -38.763 | -48.001 | -27.62 | -10.871 | -6.645 | -3.369 | -0.018 | -0.031 | -0.021 |
| EBITDA Ratio
| -7.424 | -14.687 | -12.278 | 0 | -17.325 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |